Bioabsorbable Scaffolds: The Next Holy Grail?
|
|
- Elvin Douglas
- 6 years ago
- Views:
Transcription
1 Bioabsorbable Scaffolds: The Next Holy Grail? New Cardiovascular Horizons New Orleans, LA June 06, 2013 Lewis B. Schwartz, M.D., F.A.C.S. Vascular Surgery and Endovascular Therapy University of Chicago
2 Rationale for the Development of Bioresorbable Vascular Scaffolds Limitations of metallic stents restenosis stent thrombosis chronic inflammation imaging artifacts jailed side branches inhibition of positive remodeling (shear stress adaptation) prevention of normal physiologic function such as vasomotion need for prolonged anti-platelet therapy permanent implant complicating repeat intervention Adapted from Waksman R. Update on bioabsorbable stents: From bench to bedside. J Interven Cardiol 2006;19:
3 Igaki-Tamai PLA Stent Stone GW. The Promise of ABSORB Bioabsorbable Vascular Scaffolds. Cardiovascular Revascularization Technologies; 2013 February 25; Washington. 3 Hideo Tamai
4 Bioresorbable Scaffolds 9-year follow-up PRE-PROCEDURE POST-DILATION 9-YEARS Onuma Y, Garg S, IOkamura T, Ligthart J, Jan van Geuns R, de Feyter PJ, et al. Ten-year follow-up of the IGAKI-TAMAI stent. A posthumous tribute to the scientific work of Dr. Hideo Tamai. Euroint. 2009;5 (suppl F):F109-F11.
5 Igaki-Tamai long-term results Nishio S, Kosuga K, Igaki K, Okada M, Kyo E, Tsuji T, et al. Long-term (>10 years) clinical outcomes of first-in-man biodegradable poly-l-lactic acid coronary stents: Igaki-Tamai Stents. Circ. 2012;
6 Bioresorbable Coronary Scaffolds Reported Clinical Studies Device Study Drug Lesions n Outcome Igaki-Tamai FIM none coronary 50 18% 12-months 28% 10-years Igaki-Tamai PROGRESS AMS none coronary 63 48% 12-months AMS (Biotronik) BIOSOLVE-I paclitaxel coronary 22 10% 6-months 24 in-scaffold LLL months REVA RESORB 30 67% 6-months none coronary RESTORE I 22 2 ABSORB Cohort A 30 12% 6-months ABSORB Cohort B everolimus coronary % 6-months % 12-months ABSORB (Abbott) ABSORB Extend % 6-months DESolve I novolimus coronary 15 0% DESolve (Elixir)
7 Abbott Vascular Everolimus Eluting Bioresorbable Vascular Scaffold Components Scaffold Coating Drug Delivery system Bioresorbable Bioresorbable Everolimus XIENCE V Poly(L-lactide) (PLLA) Naturally resorbed, fully metabolized Poly(D,L-lactide) (PDLLA) coating Naturally resorbed, fully metabolized Similar dose density and release rate to XIENCE V World-class deliverability Photos taken by and on file at Abbott Vascular.
8 Absorb v. Cypher Absorb 1 month 6 months 1 year 2 years 3 years 4 years Cypher Representative photomicrographs of porcine coronary arteries, 2x Photos taken by and on file at Abbott Vascular. Tests performed by and data on file at Abbott Vascular.
9 BVS Cohort A Degradation on the Bench and in Porcine Coronary Arteries Virmani R. Challenges for the development of biodegradable scaffolds: Insight from the preclinical trials. Cardiovascular Research Technologies; 2013 February 25; Washington.
10 Post-procedure Pre-procedure A B C D E A B C D E
11 A B C D E A B C D E
12 The Lancet 2008;371: lesions Pre-procedure Lesion length (mm) 8.66 RVD (mm) 2.78 MLD (mm) 1.10 DS (%) 59% Post-procedure In-stent MLD (mm) 2.33 In-stent DS (%) 16% In-stent acute gain (mm) mos. follow-up In-stent MLD (mm) 1.88 In-stent DS (%) 27% In-stent late loss (mm) 0.44 ± 0.35 In-stent ABR (%) 11.5%
13 In-stent late loss (mm) Comparison of DES - Late Lumen Loss 4 mos 6 mos 8/9 mos 12 mos CYPHER TAXUS ENDEAVOR XIENCE V
14 ABSORB Cohort A Temporal Lumen Dimensional Changes, Per Treatment Post-PCI n = 25 6 Mos. n = 25 ABSORB Cohort A Scaffold Area MLA = 5.09mm % 3.92mm 2 Late Loss = 0.43 mm Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. The Lancet 2009;373:
15 ABSORB Cohorts A & B Lower MCUSA (maximum unsupported scaffold area) More even support of arterial wall More uniform strut distribution Lower late stent area loss Improved stent retention Unchanged material and strut thickness Onuma Y, Piazza N, Ormison JA, Serruys PW. Everolimus-eluting bioarbsorbable stent - Abbott Vascular programme. Euroint 2009;5(suppl F):F98-F ;373: Gomez-Lara J, Brugaletta S, Diletti R, Garg S, Onuma Y, Gogas BD, et al. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur Heart J 2010.
16 Radial Strength Oberhauser JP, Hosseiny S, Rapoza RJ. Design principles and performance of bioresorbable polymeric coronary scaffolds. EuroInt. 2009;5 (suppl F):F15-F22.
17 ABSORB Cohorts A & B COHORT A COHORT B 6-mos. Postprocedure Postprocedure 6-mos. Gomez-Lara J, Brugaletta S, Diletti R, Garg S, Onuma Y, Gogas BD, et al. A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur Heart J 2010.
18 % Patients ABSORB Cohort B: 6-Month QCA Intent to Treat Cumulative Incidence Curve for Late Loss 100% 90% 80% 70% 0.10 ± 0.23 mm 0.85 ± 0.36 mm 60% 0.43 ± 0.37 mm 50% 40% 30% 20% 0.19 ± 0.18 mm BVS Cohort A (N = 26) BVS Cohort B (N = 42) Xience EES* (N = 23) Vision BMS* (N = 27) 10% 0% In-Stent Late-Loss (mm) *SPIRIT First Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: Six-month clinical and imaging outcomes. Circ. 2010;122(22): ABSORB is neither approved nor available for sale in the U.S.
19 ABSORB Cohort B two-year results Pre- Absorb Immediately Post Absorb 6 Months 2 Years Ormiston J, Serruys PW. ABSORB Cohort B Trial Two year clinical and angiographic results of the ABSORB everolimus eluting bioresorbable vascular scaffold (poster). Transcatheter Cardiovascular Therapeutics; 2011 November 8; San Francisco, CA.
20 Angiographic late lumen loss two-year results In-stent or scaffold LLL (mm) Taxus (Park) Taxus (ISAR- TEST 2) Cypher (Park) Cypher (ISAR- TEST 2) Cypher (ISAR- TEST 4) Cypher (ISAR- TEST-3) Xience (ISAR TEST 4) Absorb (Cohort B) Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schömig A, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. J Am Coll Cardiol: Cardiovasc Interv. 2009;2: Byrne RA, Kufner S, Tiroch K, Massberg S, Laugwitz K-L, Birkmeier A, et al. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis (ISAR-TEST-3): 2-year follow-up results. Heart. 2009;95: Park KW, Kim C-H, Lee H-Y, Kang H-J, Koo B-K, Oh B-H, et al. Does late catch-up exist in drug-eluting stents: Insights from a serial quantitative coronary angiography analysis of sirolimus versus paclitaxel-eluting stents. Am Heart J. 2010;159: Ormiston J, Serruys PW. ABSORB Cohort B Trial Two year clinical and angiographic results of the ABSORB everolimus eluting bioresorbable vascular scaffold (poster). Transcatheter Cardiovascular Therapeutics; 2011 November 8; San Francisco, CA. Byrne RA, Kastrati A, Tiroch K, Massberg S, Wieczorek A, Laugwitz K-L, et al. Two-year outcomes after everolimus- or sirolimus-eluting stents in patients with coronary artery disease in the ISAR-TEST 4 Trial. Transcatheter Cardiovascular Therapeutics; 2010; San Francisco, California.
21 Absorb v. XIENCE V at 2-years MACE (C-Death, MI, ID-TLR) 22% 20% 18% 16% 14% 12% 10% 8% 6% 4% 2% 0% ABSORB BVS(B1+B2) XV (3.0 x 18mm subgroup, SPI+SPII+SPIII RCT) Time Post Index Procedure (Months) 758-day HR 0.97 [0.42,2.21] p= % 7.9% Days Absorb XIENCE V Rapoza R. Absorb BVS Program: Long-term experimental data angiography, IVUS, OCT, histology and micro CT. Local Drug Delivery and Cardiovascular Course on Revascularisation; 2012 February 4; Geneva, Switzerland. ABSORB and XIENCE V are trademarks of the Abbott Group of Companies
22 QCA post procedure Post procedure Preprocedure MLD 2.45mm FUP before vasomotion 5 Min. After Methergine After Nitro Mean LD -0.60mm (-22%) Minimal LD 1.58 mm Mean LD 2.12 mm Mean LD +0.55mm (+26%) Minimal LD 2.32 mm Mean LD 2.67 mm MLD 2.46 mm Mean LD 2.72mm Late Loss: -0.01mm
23 in Vessel Diameter (mm) (pre-drug infusion to post-drug infusion) Vasoconstriction Vasodilation Recovery of Vasoreactivity after Absorb Implantation 1 6 Months 1 12 Months 2 24 Months 3 ABSORB Cohort B1 ABSORB Cohort B2 ABSORB Cohort A 0.5 (n=15) (n=6) (n=19) (n=13) (n=9) (n=7) Acetylcholine -1 Methergine Simonton C. The Abbott Vascular DES Pipeline. Cardiovascular Research Technologies; 2013 February 25; Washington. 1. Adapted from Serruys, PW. ACC Adapted from Serruys, PW. ACC Adapted from Serruys, PW, et al. Lancet 2009; 373:
24 Okamura T, Serruys PW, Regar E. The fate of bioresorbable struts located at a side branch ostium: serial three-dimensional optical coherence tomography assessment. Euroint. 2010; doi: /eurheartj/ehq175; online publish-ahead-of-print 31 May ABSORB Cohort A: 24-Month Results
25 ABSORB Cohort B - Late Lumen Enlargement by IVUS Post-PCI 6 Months 2 Years N = 33 N = 33 N = 33 ABSORB Cohort B Serial Analysis Scaffold Area Lumen Area 6.53 mm 2 1.7% 6.36 mm mm 2 Lumen Area 7.2% Late Loss = 0.19 mm Ormiston J, Serruys PW. ABSORB Cohort B Trial Two year clinical and angiographic results of the ABSORB everolimus eluting bioresorbable vascular scaffold (poster). Transcatheter Cardiovascular Therapeutics; 2011 November 8; San Francisco, CA.
26 ABSORB EXTEND Non-Randomized, Single-Arm, Continued Access Trial Clinical Follow-Up ~1,000 subjects Up to 100 global sites (non-us) Follow-up (months) MSCT follow up (n=100) OCT, IVUS follow up (n=50) Study Objective Continued Access trial. FPI: Jan 11, 2010 Endpoints Treatment Device Sizes Typical PCI clinical endpoints Up to 2 de novo lesions in different epicardial vessels Planned overlapping allowed in lesions >22 and 28 mm Scaffold diameters: 2.5, 3.0, 3.5 mm Scaffold lengths: 12*, 18, 28 mm Bartorelli, A, An Interim Report on the 12-Month Clinical Outcomes from the First 250 Patients Registered, and An Interim Report on the 6-Month Clinical Outcomes from the First 500 Patients Registered, TCT 2012 Simonton C. The Abbott Vascular DES Pipeline. Cardiovascular Research Technologies; 2013 February 25; Washington.
27 ABSORB EXTEND Non-Randomized, Single-Arm, Continued Access Trial Intent to Treat (ITT) Analysis Interim Snapshot Bartorelli, A, An Interim Report on the 12-Month Clinical Outcomes from the First 250 Patients Registered, and An Interim Report on the 6-Month Clinical Outcomes from the First 500 Patients Registered, TCT 2012 Simonton C. The Abbott Vascular DES Pipeline. Cardiovascular Research Technologies; 2013 February 25; Washington.
28
29 The ABSORB Clinical Trials ABSORB Cohort A n = 30; FIM ABSORB Cohort B n = 101; FIM ABSORB Extend n = up to 1,000 ABSORB II n = ~330 ABSORB PHYSIOLOGY n = ~35 ABSORB FIRST n = 10,000 ABSORB III n = ~1,502 ABSORB Japan n = ~265 ABSORB China n = ~200 5 Y 1 Y 2 Y 3 Y 4 Y 5 Y Enrollment & Follow-Up Enrollment & Follow-Up Enrollment & Follow-Up 1 Y 1 Y Enrollment & Follow-Up Enrollment & Follow-Up 2 Y 3 Y 1 Y 2 Y Enrollment & Follow-Up Enrollment & Follow-Up 2 Y 3 Y 1 Y 1 Y 1 Y 2 Y 1 Y 2 Y 3 Y 2 Y 2 Y Total Absorb Pts Studied n=~599 n~965 n~5,709 n~13,463 n~13,463 n~13,463 Simonton C. The Abbott Vascular DES Pipeline. Cardiovascular Research Technologies; 2013 February 25; Washington.
30 BVS Implantation Technique Use online QCA Avoid under sizing, as postdilation is limited to 0.5 mm Proper lesion preparation = sufficient large balloon (min 2.5 mm) Use more supportive wires Direct stenting possible in ACS Van Geuns R-J. BVS Expand: First results of wide clinical applications. Cardiovascular Research Technologies; 2013 February 25; Washington.
31 Bioresorbable Scaffolds - Ongoing Clinical Studies Device Company Study Drug Lesions n Status DREAMS AMS Biotronik BIOSOLVE I paclitaxel coronary 56 in-scaffold LLL months ReZOLVE Reva Medical, Inc. RESTORE I none coronary 22 2 months RESTORE II sirolimus 125 enrolling ABSORB EXTEND 1000 enrolling Abbott everolimus coronary ABSORB ABSORB III 2000 enrolling Elixir Medical DESolve I novolimus coronary 16 in-scaffold LLL 0.19 months DESolve DESolve Nx 126 enrolled
32 The Resorbable Holy Grail Restoration of normal vasomotion, with NO production Restoration of normal shear stress and cyclic strain Restoration of normal vessel curvature Reduced risk of very late polymer reactions Avoidance/resolution of positive remodeling and stent malapposition Avoidance/resolution of late strut fractures Less neoatherosclerosis Un-jailing of side-branches Plaque regression MRI/CT imaging follow-up The return of normal vessel architecture Stone GW. The Promise of ABSORB Bioabsorbable Vascular Scaffolds. Cardiovascular Revascularization Technologies; 2013 February 25; Washington.
Best Strategy is Still Out There: Bioresorbable Vascular Scaffold (BVS) and New Technology?
Best Strategy is Still Out There: Bioresorbable Vascular Scaffold (BVS) and New Technology? ARCH St. Louis Craig M. Walker, MD, FACC, FACP Clinical Professor of Medicine Tulane University School of Medicine
More informationStephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank
From ABSORB Cohort A to ABSORB III and IV Randomized Trials Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank Disclosures Consultant, Abbott Vascular
More informationBioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals
Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationProspective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results
Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and 5Y clinical and imaging results Stefan Verheye, MD PHD ZNA Middelheim Antwerp, Belgium Potential
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationBioresorbable stents for all or for few? Franz-Josef Neumann
Bioresorbable stents for all or for few? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria, consultancy fees and research grants from Lilly, Daiichi Sankyo, Sanofi-Aventis,
More informationCurrent Status of BioresorbableScaffolds: Moving Forward or Backwards?
Evolving Science of Stents Current Status of BioresorbableScaffolds: Moving Forward or Backwards? Christian W. Hamm Kerckhoff Heart and Thorax Center Bad Nauheim and Medical Clinic I, University of Giessen,
More informationΑ-Δ. ΜΑΥΡΟΓΙΑΝΝΗ ΚΑΡΔΙΟΛΟΓΟΣ AIMOΔΥΝΑΜΙΚΟ ΕΡΓΑΣΤΗΡΙΟ Γ.Ν.Θ. «Γ.ΠΑΠΑΝΙΚΟΛΑΟΥ» ΘΕΣΣΑΛΟΝΙΚΗ
Α-Δ. ΜΑΥΡΟΓΙΑΝΝΗ ΚΑΡΔΙΟΛΟΓΟΣ AIMOΔΥΝΑΜΙΚΟ ΕΡΓΑΣΤΗΡΙΟ Γ.Ν.Θ. «Γ.ΠΑΠΑΝΙΚΟΛΑΟΥ» ΘΕΣΣΑΛΟΝΙΚΗ Mr. cab driver, age 49 random thoughts RCA has already long stenting, which has evidently ISR and the proper amount
More informationDISAPPEARING STENT: IS THE TIME APPEARED?
DISAPPEARING STENT: IS THE TIME APPEARED? Carlo Cernetti Chief Cardiology Division San Giacomo Hospital Castelfranco Veneto (TV) 1 THE BEGINNING START randomized study (n=452) Long-term follow-up The benefit
More informationThe role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium
The role of bioabsorbable stents in the superficial femoral artery What is going on? Frank Vermassen Ghent University Hospital Belgium Disclosures Speaker name: Frank Vermassen I have the following potential
More informationINTERVENTIONAL CARDIOLOGY Bioresorbable Stents Update: Similarities. Generation BVS
INTERVENTIONAL CARDIOLOGY 2017 32 ND ANNUAL INTERNATIONAL SYMPOSIUM Bioresorbable Stents Update: Similarities and Differences in Comparison to First Generation BVS Dariusz Dudek Institute of Cardiology
More informationCatch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
More information生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所
生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所 PCI milestones Pre Post Biodegradable polymer? 1 st revolution 1977 PTCA 2 nd revolution 1988 BMS 3 rd revolution 2000 DES Bioresorbable
More informationPresente e futuro degli stents bio-riassorbibili: fact or finction? Francesco Bedogni IRCCS Policlinico San Donato
Presente e futuro degli stents bio-riassorbibili: fact or finction? Francesco Bedogni IRCCS Policlinico San Donato Igaki-Tamai stent at 10 years! C D E Gold markers * E * B D C A B * * A Onuma Y et al.
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationFrom a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.
Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationOCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?
OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research
More informationBioabsorbable Scaffolding: Technology and Clinical Update. PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland
Bioabsorbable Scaffolding: Technology and Clinical Update PD Dr. Nicolas Diehm, MD, FESC Inselspital, University Hospital Bern, Switzerland Disclosures I am not Ron Waksman 1 Clinical experience with AMS
More informationBioresorbable Stents: Innovation or Bust?
Bioresorbable Stents: Innovation or Bust? Rajiv Jauhar, MD FACC, FSCAI Chief of Cardiology Director of Cardiac Cath Labs Northshore University Hospital San Diego July, 2016 Conflict of Interest Disclosure
More informationPolymer-Free Stent CX - ISAR
Polymer-Free Stent CX - ISAR Moo Hyun Kim, MD, FACC on behalf of Dr. Florian Krackhardt, Germany CX ISAR Stent : Features Intracoronary Stenting and Angiographic Results Strut Thickness of only 50/60 μm
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationResults of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators
Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationDisclosure Eberhard Grube, M.D.
Disclosure Eberhard Grube, M.D. I disclose the following financial relationships: Consultant Sadra Medical, Core Valve, Biosensors, Orbus Neich, Cordis Johnson & Johnson, Boston Scientific, Mitralign,
More informationΕνδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον. Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ
Ενδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ DES Penetration -(2011) Source: Millenium Research Group Cordis has stopped manufacturing
More informationFANTOM II trial: Clinical results from the Fantom Sirolimus-Eluting BRS. Norbert Frey, MD University of Kiel, Germany
FANTOM II trial: Clinical results from the Fantom Sirolimus-Eluting BRS Norbert Frey, MD University of Kiel, Germany Potential conflicts of interest Speaker's name: Dr. Norbert Frey I have the following
More informationTaking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationInnovation in Cardiovascular Interventions. New DES, Scaffolds and other Devices Have Angioplasty Results Improved
Innovation in Cardiovascular Interventions New DES, Scaffolds and other Devices Have Angioplasty Results Improved Alexandra Lansky, MD Yale University School of Medicine University College of London DES
More informationBioresorbable Scaffolds Moving Forward or Backwards?
Bioresorbable Scaffolds Moving Forward or Backwards? George D. Dangas, MD, FACC, MSCAI Professor of Cardiology & Vascular Surgery Icahn School of Medicine at Mount Sinai New York, NY Disclosure Statement
More informationBiodegradable Stents An update and work-in
Biodegradable Stents An update and work-in in-progress Department of Cardiology, Hideo Tamai, M.D. Metallic stents... Background induce a varing degree of thrombogenesis eg, subacute thrombosis in complex
More informationAbsorbable Scaffolds the Future of Coronary Interventions?
Absorbable Scaffolds the Future of Coronary Interventions? Brock Cookman, DO, MSA Interventional Cardiology Mercy Heart and Vascular Institute April 8, 2017 None Disclosures Objectives History of cardiac
More informationBioresorbable polymeric scaffolds for coronary revascularization: Lessons learnt from ABSORB III, ABSORB China, and ABSORB Japan
OPEN ACCESS Lessons from the trials Bioresorbable polymeric scaffolds for coronary revascularization: Lessons learnt from ABSORB III, ABSORB China, and ABSORB Japan Bill D. Gogas*, Spencer B. King III,
More informationReZolve2 Bioresorbable Coronary Scaffold Clinical Program Update
ReZolve2 Bioresorbable Coronary Scaffold Clinical Program Update Dr. David Muller St Vincent s Hospital Sydney, Australia 0 Potential conflicts of interest Speaker's name: Dr. David Muller I do not have
More informationBVS: indicazioni e limiti alla luce degli attuali dati disponibili. Luca Testa, MD, PhD Istituto Clinico S. Ambrogio Milano
BVS: indicazioni e limiti alla luce degli attuali dati disponibili Luca Testa, MD, PhD Istituto Clinico S. Ambrogio Milano Trends in PCI: Improvement in Patient Outcomes with the Opportunity for Further
More informationLate Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance
Late Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance Richard Kuntz Brigham and Women s s Hospital Harvard Medical School Late Loss and DES Brief history of Late Loss
More informationCYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer
Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time
More informationResults of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators
Comparison of the ABSORB TM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (Xience TM ) in Acute ST-Elevation Myocardial Infarction: Results of TROFI II Study.
More informationDrug eluting stents From revolution to evolution. Current limitations
Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective
More informationBernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the XIENCE Everolimus Eluting Stent Bernard Chevalier
More informationIN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
More informationSide branch occlusion in 500 ABSORB BVS
Side branch occlusion in 500 ABSORB BVS Clinical implications and Solutions Robert-Jan van Geuns, MD, PhD Associate Professor,Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands On behalf
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationBernard Chevalier Institut Jacques Cartier, Massy, France. Patrick W. Serruys Imperial College, London, UK Erasmus University MC, Netherlands
The 4-year Clinical Outcomes of the ABSORB II Trial: First Randomized Comparison between the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold and the Everolimus Eluting Stent Bernard Chevalier
More informationVascular Intervention // Coronary Drug-Eluting Stent System. Orsiro. Clinically proven. Highly deliverable. Ultrathin 60 μm struts
Vascular Intervention // Coronary Drug-Eluting Stent System Clinically proven Highly deliverable Ultrathin 60 μm struts The new benchmark for DES BIOFLOW-V 12-month clinical outcomes compared to Xience
More informationMagmaris Stent (Biotronik) A Pichard, Ron Waksman. Medstar Washington Hospital Center Washington, DC
Magmaris Stent (Biotronik) A Pichard, Ron Waksman. Medstar Washington Hospital Center Washington, DC Conflict of Interest None for this presentation Downside of Metallic Stents 1. Restenosis No longer
More informationDRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
More informationPatrick W. Serruys MD. PhD. 1 Bernard Chevalier MD. 2 Yoshinobu Onuma MD. PhD. 3 on behalf of ABSORB II investigators
TCT 216, Washington convention center October 3 th 216, 8:3 am- Room 159 Level 1 Late breaking clinical trial and First report investigations Press Conf.1 ABSORB II: Three-year Clinical Outcomes from a
More informationDrug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition
Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition Prof Martin Rothman on behalf of Dr. Stephen G. Worthley Alexandre Abizaid, Ajay J
More informationSecond Generation Drug Eluting Stents: From Inhibition to Healing
Second Generation Drug Eluting Stents: From Inhibition to Healing Mitchell W. Krucoff MD, FACC Professor of Medicine / Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationBioabsorbable Scaffolds - the future, Jacques Koolen
Bioabsorbable Scaffolds - the future, a passing fad or somewhere in between? Jacques Koolen Amsterdam POBA Acute closure Restenosis 3 months 30-50% BMS DES First generation Subacute-late trombus very
More informationPatrick W. Serruys Imperial College, London, UK Erasmus University MC, Rotterdam, the Netherlands
TCT 2014 13 Sep 2014-17 Sep 2014, Washington, DC - U.S.A Plenary Session XII : Late-Breaking clinical Trials #2 ABSORB II : A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationA Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience
A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research The Cardiovascular
More informationInsights from the Magmaris Clinical Data: BIOSOLVE II and BIOSOLVE III 12 Month Follow Up
Insights from the Magmaris Clinical Data: BIOSOLVE II and BIOSOLVE III 12 Month Follow Up Ron Waksman, MD FACC FSCAI FESC Professor of Medicine, Georgetown University Director, Cardiovascular Research
More informationDrug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester
Drug eluting stents Where are we now and what can we expect in 2003? Tony Gershlick Leicester Trials Real World What we need i. Prevent restenosis cost effective Either : - Treat all at equivalent cost
More informationDES In-stent Restenosis
DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms
More informationAre New DES Designs Safer?
cit0711_f6_krucoff.qxd 8/24/11 2:03 PM Page 56 Are New DES Designs Safer? Changes in stent platform, polymer, and drug components have led to improved outcomes. BY ASHWANI SASTRY, MD, AND MITCHELL W. KRUCOFF,
More informationCoronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationDrug Eluting Stents overhyped, overused and overpriced?
Advanced Angioplasty 2008 BCIS 23 rd Jan 2008 Drug Eluting Stents overhyped, overused and overpriced? William Wijns MD, PhD Cardiovascular Center Aalst http://www.cardio-aalst.be William.Wijns@village.uunet.be
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationBiosensors Lunch Symposium
Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM
More informationTailored bifurcation therapy
Tailored bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation lesion coverage without creating a false carina Bifurcation DES technology
More informationCoronary Stents: Past, Present and Future
Kardiologie Kardio Lunch 07.04.2016 Coronary Stents: Past, Present and Future Christoph Kaiser Universitätsspital Basel Rubin GS, The first balloon-expandable coronary stent, University of Queensland Press
More informationDrug eluting balloons in CAD
Drug eluting balloons in CAD Ioannis Iakovou, MD, PhD Interventional Cardiology 1 st Cath Lab Onassis Cardiac Surgery Center Drug-Eluting Balloons (DEB) Technology and Applications 1. Special Features
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationThe Interventional Trials of the Year: (TCT, AHA, and ACC)
The Interventional Trials of the Year: 2006-2007 2007 (TCT, AHA, and ACC) Roxana Mehran, MD Associate Professor of Medicine Columbia University Medical Center Cardiovascular Research Foundation New York
More informationTLR des Stents Actifs
TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationCoronary Stents: Past, Present, Future
Coronary Stents: Past, Present, Future Michael C Kim, MD FACC Director Cath Lab and IC Lenox Hill Heart and Vascular Institute Northwell Health IC-296208-AN DEC 2016 Page 1 1st-Generation DES was not ideal
More informationWhat Stent to Use? JASVINDAR SINGH MD, FACC
What Stent to Use? JASVINDAR SINGH MD, FACC ASSOCIATE PROFESSOR OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS DIRECTOR, CARDIAC CATHETERIZATION LAB BARNES-JEWISH HOSPITAL What Stent to Use? Jasvindar
More informationINSIDE INFORMATION YOU CAN T IGNORE
INSIDE INFORMATION YOU CAN T IGNORE Volcano, the Volcano logo and SyncVision are registered trademarks of Volcano Corporation. All other trademarks set-forth are properties of their respective owners.
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Byrne RA, Stone GW, Ormiston J, Kastrati A.
More informationBiodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial
Clinical trial report Biodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial Biodegradable polymer drug-eluting stent (DES) platforms have the
More informationPCI with Polymer-free Stent
PCI with Polymer-free Stent Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany Drug Eluting Stents: Present Coating Technology Solution
More informationEmerging Cardiac Technologies. Thomas D. Conley, MD FACC FSCAI BHHI Primary Care Symposium February 27, 2015
Emerging Cardiac Technologies Thomas D. Conley, MD FACC FSCAI BHHI Primary Care Symposium February 27, 2015 None Financial Disclosures Examples of Emerging Technologies Therapeutic Bioabsorbable Stents
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationIn-stent Restenosis Diagnostic and Therapeutic Challenges. Kostis Raisakis General Hospital of Athens «G. Gennimatas»
In-stent Restenosis Diagnostic and Therapeutic Challenges Kostis Raisakis General Hospital of Athens «G. Gennimatas» Introduction With POBA, rates of acute and chronic vessel occlusion at 30% to 60%, secondary
More informationDevice and Clinical Program Highlights: SINOMED BuMA Stent
Device and Clinical Program Highlights: SINOMED BuMA Stent Runlin Gao, MD, FACC, FESC, FSCAI Fuwai Hospital, National Center for Cardiovascular Diseases, China CAMS, PUMC BuMA Supreme Platform and Pre-Clinical
More informationNew joy of cardiac disease
New joy of cardiac disease Coronary artery disease CT coronary angiography The bioabsorbable stent Valvular heart disease Percutaneous aortic valve replacement Mitral clip for mitral incompetence Arrhythmias
More informationΑγγειοπλαστική σε Eπαναστενωτικές Bλάβες
Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)
More informationNon-LM bifurcation studies of importance in 2011
7th European Bifurcation Club 14-15 October 2011 LISBON Goran Stankovic MD, PhD Non-LM bifurcation studies of importance in 2011 October 15 th : 08:00 08:10 DKCRUSH-II: A Prospective Randomized Trial of
More informationNEW GENERATION DES WITH NEW GENERATION POLYMERS. Prof. Dr. Rainer Wessely, Duisburg, Germany
NEW GENERATION DES WITH NEW GENERATION POLYMERS Prof. Dr. Rainer Wessely, Duisburg, Germany Sousa J et al., JACC Cardioasv Interv 2010 10 years DES NEXT DES BMS + DAPT DES DES + DAPT S A F E T Y BMS E
More informationThe need for mechanical support for dilated vessels
Implantation Technique for Bioresorbable Scaffolds Device description and patient/lesion selection with the Absorb BVS. BY JIANG MING FAM, MD, MBBS, AND ROBERT-JAN van GEUNS, MD, PhD, FESC, FACC The need
More informationTechnical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center, Athens, Greece Critical issues in LM PCI Anatomic variability Techniques Variability
More informationElement Clinical Program Perseus Late Breaking News and the Platinum Study Design
Element Clinical Program Perseus Late Breaking News and the Platinum Study Design Ian T. Meredith MBBS, BSc(Hons), Ph.D, FRACP, FACC, FCSANZ, FSCAI, FAHA, FAPSIC Professor and Director of Monash HEART
More informationThe Future Landscape of DES: New Stent Platforms, Drug Carriers, and Recent Experiences
13 th Angioplasty Summit 2008 TCT Asia Pacific The Future Landscape of DES: New Stent Platforms, Drug Carriers, and Recent Experiences Eberhard Grube MD FACC, FSCAI HELIOS Heart Center Siegburg, Germany
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationYukon Chrome PC. Translumina trust is what counts. Sirolimus Eluting CoCr Coronary Stent System. 5-Years Randomized Clinical Follow-Up
Sirolimus Eluting CoCr Coronary Stent System Yukon Chrome PC 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts Yukon Chrome PC DES coating with excellent long-term
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationFuture Developments in Coronary Stenting. Keith D Dawkins MD FRCP FACC Southampton University Hospital UK
Future Developments in Coronary Stenting Keith D Dawkins MD FRCP FACC Southampton University Hospital UK Conflicts of Interest Research Grant Support Boston Scientific Corporation Advisory Board/Consultant
More informationBiolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program
TCT Asia 2006 Biolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program Eberhard Grube MD FACC, FSCAI HELIS Heart Center Siegburg,
More informationΝεότερα DES stents. Δεδοµένα εφαρµογής των και προοπτικές
Νεότερα DES stents. Δεδοµένα εφαρµογής των και προοπτικές Δηµήτρης Γ. Σιώνης Αιµοδυναµικό Τµήµα Επεµβατικής Καρδιολογίας Σισµανόγλειο-Αµ. Φλέµιγκ ΓΝ Αθήνα Δήλωση συµφερόντων None for the presentation Potential
More information